Gilla Kaplan sold $529k of TYRA
director at Tyra Biosciences, Inc.. 14,295 shares at an average of $36.97, traded Mar 25, 2026, filed Mar 27, 2026.
Score components
- +15RoleDirector
- +18Trade size$529k at market
- +10Share of holdings soldSold 34% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.6%, 3m -12.2%, 6m -40.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-129239, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | MOption exercise Common Stock | +14,295 | $2.25 | $32k | 42,526 | Mar 27, 2026 |
| Mar 25, 2026 | SOpen-market sale Common Stock | -14,295 | $36.97 | $529k | 28,231 | Mar 27, 2026 |
| Mar 26, 2026 | MOption exercise Common Stock | -53,172 | $2.25 | $120k | 81,403 | Mar 27, 2026 |
| Mar 26, 2026 | DDisposition to issuer Common Stock | -53,172 | $37.75 | $2.0M | 28,231 | Mar 27, 2026 |
| Mar 25, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -14,295 | $0.00 | $0 | 53,172 | Mar 27, 2026 |
| Mar 26, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -53,172 | $0.00 | $0 | 0 | Mar 27, 2026 |
Related signals
Other insiders at Tyra Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TYRAbuy Tyra Biosciences, Inc. | Rehan Verjee director | $20k 972 shares | - | |
| 8Weak | Tyra Biosciences, Inc. | Daniel Bensen Chief Discovery Officer | $263k 8,000 shares | -5% | |
| 8Weak | Tyra Biosciences, Inc. | Daniel Bensen Chief Discovery Officer | $228k 8,000 shares | -5% | |
| 16Weak | Tyra Biosciences, Inc. | Robert J More director | $250k 10,000 shares | -0% | |
| 15Weak | Tyra Biosciences, Inc. | Daniel Bensen Chief Discovery Officer | $181k 8,000 shares | -5% | |
| 28Weak | Tyra Biosciences, Inc. | Robert J More director | $5.0M 246,871 shares | -6% | |
| 43Moderate | Tyra Biosciences, Inc. | Daniel Bensen Chief Operating Officer | $2.0M 125,589 shares | -42% | |
| 43Moderate | Tyra Biosciences, Inc. | Daniel Bensen Chief Operating Officer | $2.1M 131,411 shares | -31% | |
| 35Weak | TYRAsell Tyra Biosciences, Inc. | Gilla Kaplan director | $94k 9,578 shares | -25% | |
| 53Moderate | TYRAsell Tyra Biosciences, Inc. | Gilla Kaplan director | $535k 51,814 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.